Physical purgatives include which of the following:
Rationale:
Physical purgatives include dioctyl sodium sulphosuccinate. This agent acts as a surfactant or stool softener, physically facilitating the passage of fecal matter by increasing water and fat penetration into the stool, thereby softening it without stimulating intestinal motility. It contrasts with irritant purgatives that provoke muscular contractions to induce bowel movements, making it a true physical purgative.
B: Bisacodyl is a stimulant laxative that induces bowel movement through direct irritation of the intestinal mucosa, enhancing peristalsis rather than softening stool physically.
C: Castor oil functions as a stimulant purgative by promoting intestinal muscle contractions through ricinoleic acid, not by softening stool physically.
D: Croton oil is a powerful irritant purgative that causes intense mucosal inflammation and stimulates bowel movements, lacking the physical softening action characteristic of physical purgatives.
Which antiemetic selectively blocks levodopa induced vomiting without blocking its antiparkinsonian action?
Rationale:
Domperidone selectively blocks levodopa-induced vomiting without interfering with its antiparkinsonian effect. Domperidone acts peripherally on dopamine receptors in the gastrointestinal tract, preventing nausea and vomiting caused by levodopa without crossing the blood-brain barrier, thus preserving levodopa’s central therapeutic action on Parkinson’s disease symptoms. This selective action makes it ideal for managing levodopa side effects.
A: Metoclopramide crosses the blood-brain barrier and blocks central dopamine receptors, reducing levodopa’s efficacy in Parkinson’s treatment while controlling nausea, thus it does not selectively preserve antiparkinsonian effects.
B: Cisapride primarily enhances gastrointestinal motility via serotonin receptors and lacks selective anti-dopaminergic action necessary to counter levodopa-induced vomiting without affecting brain dopamine pathways.
D: Ondansetron blocks serotonin 5-HT3 receptors and does not target dopamine receptors responsible for levodopa-induced nausea, making it ineffective in selectively preventing levodopa-related vomiting while maintaining its therapeutic effect.
A 45-year-old man with a duodenal ulcer was treated with a combination of drugs intended to heal the mucosal damage and to eradicate Helicobacter pylori. An antibacterial drug that is used commonly to eradicate intestinal Helicobacter pylori is
Rationale:
Clarithromycin is commonly used to eradicate Helicobacter pylori because it effectively inhibits bacterial protein synthesis, making it a key component in combination therapy for duodenal ulcers caused by this infection. It has proven efficacy against H. pylori and is well-tolerated, contributing to higher eradication rates and mucosal healing when combined with other agents.
A: Cefazoline lacks significant activity against Helicobacter pylori and is not part of standard treatment regimens targeting this organism, limiting its usefulness in eradicating the bacteria responsible for duodenal ulcers.
B: Ciprofloxacin is not a primary choice for H. pylori eradication due to resistance issues and less effectiveness compared to macrolides like clarithromycin in standard triple therapy.
D: Clindamycin is rarely used against H. pylori as it does not have reliable efficacy or approval in standard eradication protocols, making it unsuitable for this infection.
Hepatitis B vaccine is least likely to be recommended for prophylactic use in
Rationale:
Hepatitis B vaccine is least likely to be recommended for prophylactic use in raw oyster eaters. This group does not have a significantly increased risk of hepatitis B virus (HBV) infection, as HBV is primarily transmitted through blood and bodily fluids, not through contaminated food like oysters. Therefore, routine vaccination is not typically targeted at them.
A: Dialysis patients Dialysis patients face frequent blood exposure, increasing their susceptibility to HBV infection, thus warranting routine vaccination to prevent transmission in healthcare settings.
B: Intravenous drug abusers Intravenous drug abusers have high HBV risk due to needle sharing, necessitating prophylactic vaccination to reduce transmission through contaminated blood.
C: Newborns Newborns receive hepatitis B vaccination to prevent vertical transmission from mother to child, a critical step in reducing chronic HBV infection rates early in life.
The following laxative lowers blood ammonia level in hepatic encephalopathy.
Rationale:
Lactulose lowers blood ammonia levels in hepatic encephalopathy. Lactulose acidifies colonic contents, converting ammonia (NH3) into ammonium ion (NH4+), which is less absorbable and thus excreted. It also promotes catharsis, reducing intestinal transit time and bacterial ammonia production. This dual action effectively decreases systemic ammonia, alleviating symptoms of hepatic encephalopathy by reducing neurotoxic substances in the bloodstream.
A: Bisacodyl stimulates bowel movements but does not specifically reduce ammonia levels or alter gut flora to lower ammonia, making it ineffective for treating hepatic encephalopathy’s hyperammonemia.
B: Liquid paraffin serves as a lubricant laxative without influencing ammonia metabolism or colonic pH, hence it does not aid in decreasing blood ammonia concentration in hepatic encephalopathy.
D: Magnesium sulfate functions as an osmotic laxative, increasing water retention in the bowel but lacks mechanisms to trap or reduce ammonia, thus not lowering blood ammonia levels in hepatic encephalopathy.
As part of a comprehensive management strategy to treat peptic ulcer disease, patients should be encouraged to do all of the following except
Rationale:
Patients should be encouraged to do all of the following except eat only bland foods.
Bland foods are not universally required in peptic ulcer disease management; evidence shows no significant benefit of strict bland diets, whereas other lifestyle modifications like reducing irritants help prevent ulcer exacerbation and promote healing more effectively.
A: Decrease caffeine ingestion Reducing caffeine intake minimizes gastric acid secretion, which can aggravate ulcers, making this a beneficial recommendation in managing peptic ulcer disease.
C: Stop smoking Smoking impairs mucosal defense and delays ulcer healing, so cessation is crucial in comprehensive peptic ulcer treatment to enhance recovery and reduce recurrence.
D: Avoid alcohol Alcohol consumption irritates the gastric mucosa and increases acid production, contributing to ulcer formation and impaired healing, thus avoiding it is an essential management strategy.
A vasodilator that can be inactivated by proteolytic enzymes is
Rationale:
A vasodilator that can be inactivated by proteolytic enzymes is Neuropeptide Y. Neuropeptide Y acts as a potent vasodilator but is susceptible to degradation by proteolytic enzymes, which cleave its peptide bonds, thereby reducing its biological activity. This enzymatic inactivation regulates its vasodilatory effects and modulates vascular tone dynamically within physiological and pathological contexts.
A: Angiotensin I Angiotensin I is a precursor peptide converted to angiotensin II and does not primarily serve as a vasodilator; it is not typically inactivated by proteolytic enzymes in a way that modulates vasodilation.
B: Isoproterenol Isoproterenol is a synthetic catecholamine that stimulates beta-adrenergic receptors causing vasodilation, but it is not a peptide and thus not inactivated by proteolytic enzymes.
C: Histamine Histamine induces vasodilation through receptor activation and is metabolized enzymatically, but not specifically by proteolytic cleavage, differing from peptide degradation mechanisms.
The following drug is an inhibitor of gastric mucosal proton pump.
Rationale:
Lansoprazole inhibits the gastric mucosal proton pump.
Lansoprazole selectively blocks the H+/K+ ATPase enzyme located in gastric parietal cells, thereby suppressing acid secretion. This proton pump inhibition leads to reduced gastric acidity, providing effective treatment for acid-related disorders such as GERD and peptic ulcers by directly targeting the final step of acid production.
A: Carbenoxolone sodium primarily enhances mucosal defense by increasing mucus production, not by inhibiting gastric acid secretion through the proton pump mechanism.
B: Sucralfate acts as a mucosal protectant by forming a protective barrier over ulcers, without affecting acid secretion or proton pump activity.
C: Famotidine is an H2 receptor antagonist that reduces acid secretion by blocking histamine receptors, not by directly inhibiting the proton pump enzyme.
A patient who must take verapamil for hypertension and angina has become severely constipated. Which of the following drugs would be most suitable as a cathartic?
Rationale:
Magnesium hydroxide would be most suitable as a cathartic for a patient taking verapamil who is severely constipated. Magnesium hydroxide acts as an osmotic laxative, drawing water into the intestines to soften stool and stimulate bowel movements. It counteracts verapamil-induced constipation effectively without causing significant systemic side effects or interacting adversely with the calcium channel blocker.
A: Aluminum hydroxide acts as an antacid and can cause constipation, worsening the patient's condition rather than relieving it. It lacks laxative properties and would not counteract verapamil-induced constipation effectively.
B: Diphenoxylate is an antidiarrheal agent that slows intestinal motility, which would exacerbate constipation. It is unsuitable as a cathartic because it reduces bowel movements rather than promoting them.
D: Metoclopramide primarily enhances gastrointestinal motility in the upper GI tract but does not have significant laxative effects on the colon. It is not appropriate to relieve severe constipation induced by verapamil.
Direct spasmolytics include the following drugs EXCEPT:
Rationale:
Atropine sulfate is not a direct spasmolytic drug.
Direct spasmolytics act directly on smooth muscle to relieve spasms by relaxing muscle fibers; papaverine, mebeverine, and aminophylline fit this category as they directly influence smooth muscle tone, while atropine sulfate functions by blocking muscarinic receptors, exerting an indirect antispasmodic effect rather than direct muscle relaxation.
A: Aminophylline Relaxation results from phosphodiesterase inhibition, elevating cAMP in smooth muscle, which directly mitigates spasms, qualifying it as a direct spasmolytic.
C: Mebeverine This drug directly targets smooth muscle cells, reducing spasms without affecting the nervous system, confirming its role as a direct spasmolytic agent.
D: Papaverine It acts by inhibiting phosphodiesterase enzymes in smooth muscle, producing direct muscle relaxation and spasm relief, categorizing it as a direct spasmolytic.
The 'acid neutralizing capacity' of an antacid is governed by
Rationale:
The 'acid neutralizing capacity' of an antacid is governed by both the equivalent weight of the antacid and the rate at which the antacid reacts with HCl. This is because the equivalent weight determines the total amount of acid that can be neutralized, while the reaction rate affects how quickly the neutralization occurs, both critical for effective acid neutralization.
A: The equivalent weight of the antacid alone defines the capacity but ignores how fast the neutralization happens, making it incomplete as a sole determinant.
B: The pH of a 1 N solution indicates the solution’s acidity or alkalinity, not the actual neutralizing capacity or reaction dynamics of the antacid.
C: The rate of reaction affects speed but doesn’t quantify the total acid neutralized, missing the contribution of the antacid’s chemical capacity in neutralization.
Eradication of H pylori along with gastric antisecretory drugs affords the following benefit(s).
Rationale:
Eradication of H pylori along with gastric antisecretory drugs provides both faster ulcer healing and a reduced chance of ulcer relapse.
D: Combining H pylori eradication with gastric antisecretory treatment accelerates mucosal recovery and significantly decreases ulcer recurrence by removing the underlying infection and reducing acid secretion, which promotes durable ulcer resolution and long-term symptom control.
A: Faster relief of ulcer pain alone does not encompass the comprehensive benefits of eradication therapy; pain relief is symptomatic and may not imply faster healing or reduced relapse risk.
B: Faster ulcer healing is part of the benefit, but it lacks mention of relapse prevention, which is a key outcome of combined eradication and antisecretory therapy.
C: Reduced chance of ulcer relapse addresses long-term outcomes but excludes the immediate advantage of expedited ulcer healing from combination treatment.
The most important drawback of sucralfate in the treatment of duodenal ulcer is
Rationale:
The most important drawback of sucralfate in the treatment of duodenal ulcer is the need for taking a big tablet four times a day. Sucralfate requires frequent dosing due to its mode of action, which limits patient compliance. The large tablet size and multiple daily doses can reduce adherence, making it less convenient compared to other ulcer medications with simpler regimens.
A: Low ulcer healing efficacy Sucralfate actually promotes mucosal protection and healing by forming a protective barrier, so its efficacy in ulcer healing is considered adequate, not low, in therapeutic use.
B: Poor relief of ulcer pain Sucralfate provides symptomatic relief by protecting ulcer sites, so it is not primarily noted for poor pain control, making this an inaccurate drawback.
C: High incidence of side effects Sucralfate is generally well-tolerated with minimal systemic absorption, resulting in fewer side effects compared to many ulcer drugs, so side effects are not a major concern.
Antimotility drugs are contraindicated in
Rationale:
Antimotility drugs are contraindicated in acute infective diarrhoeas.
This is because antimotility agents slow intestinal motility, potentially worsening infection by retaining pathogens and toxins in the gut longer. In acute infective diarrhoeas, this can exacerbate symptoms and delay clearance of the infectious agents, increasing the risk of complications such as toxic megacolon or systemic spread of infection.
A: Mild traveler's diarrhoea Antimotility drugs can be cautiously used here as the illness is typically self-limiting and caused by non-invasive pathogens, making symptom control beneficial without major risks of harm.
C: Ileostomy patients Antimotility drugs are not contraindicated since ileostomy alters intestinal transit, but these drugs require careful use and monitoring, rather than outright avoidance.
D: Patients after anal surgery Antimotility drugs may actually help by reducing bowel frequency and discomfort post-surgery, so they are not contraindicated in this group.
Which laxative should not be used to treat acute constipation because of its slow onset of action?
Rationale:
Psyllium should not be used to treat acute constipation because of its slow onset of action. Psyllium is a bulk-forming laxative that absorbs water and increases stool bulk, which typically requires 12 to 72 hours to produce results, making it unsuitable for immediate relief in acute constipation cases. It works gradually by improving bowel regularity over time.
A: Glycerin acts quickly as a hyperosmotic laxative by drawing water into the rectum, stimulating bowel movement within minutes, making it appropriate for acute constipation treatment rather than slow in onset.
B: Bisacodyl suppository stimulates bowel muscles directly with a rapid effect, usually within 15 to 60 minutes, providing prompt relief for acute constipation.
D: Milk of magnesia, an osmotic laxative, has a relatively fast onset of 30 minutes to 6 hours, suitable for acute constipation, unlike slow-acting agents.
Which of the following statements about non-drug therapies for acute diarrhea is not correct?
Rationale:
Food should not be withheld for 6-12 hours even if the patient is not vomiting.
Option B is incorrect because withholding food can lead to malnutrition and delayed recovery. Continued feeding supports gut integrity, provides essential nutrients, and promotes faster healing during acute diarrhea episodes. Early refeeding is recommended to maintain energy and nutrient balance, which is critical for patient recovery.
A: Breast feeding should be continued as normal. Breastfeeding provides essential nutrients and immune support, aiding recovery and hydration during diarrhea, making this an accurate statement.
C: Fluids can be given to patients who experience vomiting, but small amounts of fluid should be used. Small fluid quantities help prevent dehydration and reduce vomiting risks, making this option correct.
D: Replacement fluids mainly consist of water, sugar, potassium, sodium and bicarbonates. These components are essential in oral rehydration solutions to restore electrolyte and fluid balance, validating this statement’s correctness.
Which one of the following drugs has no effect on prothrombin but increases the likelihood of bleeding in patients who are also taking warfarin?
Rationale:
Naproxen has no effect on prothrombin but increases the likelihood of bleeding in patients who are also taking warfarin. Naproxen, a nonsteroidal anti-inflammatory drug, impairs platelet function without altering prothrombin time, thereby elevating bleeding risk. This interaction heightens hemorrhagic complications in warfarin-treated individuals despite stable prothrombin levels, distinguishing it from drugs that affect clotting factors directly.
A: Carbamazepine induces hepatic enzymes, accelerating warfarin metabolism and reducing its anticoagulant effect, thus not increasing bleeding risk without affecting prothrombin directly.
B: Cholestyramine binds warfarin in the gut, decreasing its absorption and anticoagulant effect, which lowers bleeding risk rather than increasing it.
D: Rifampin induces liver enzymes, enhancing warfarin clearance and diminishing its effect, thereby reducing instead of increasing bleeding tendency.
Which one of the following agents is least likely to protect the upper gastrointestinal tract from ulcer formation?
Rationale:
Celecoxib is least likely to protect the upper gastrointestinal tract from ulcer formation. Celecoxib, a selective COX-2 inhibitor, reduces inflammation without significantly inhibiting COX-1, which protects the gastric mucosa. Therefore, it lacks the gastroprotective effects typical of other agents that either neutralize acid or enhance mucosal defenses, resulting in minimal prevention against ulcers in the upper GI tract.
A: Antacids Neutralize stomach acid, directly reducing mucosal irritation and preventing ulcer development, thereby offering significant protection to the upper gastrointestinal lining from acid-induced damage and ulcer formation.
C: Cimetidine Blocks histamine H2 receptors, reducing acid secretion and promoting ulcer healing in the upper gastrointestinal tract. Its acid-suppressive action contributes effectively to mucosal protection and ulcer prevention.
D: Misoprostol Enhances mucosal defense by stimulating prostaglandin receptors, increasing mucus and bicarbonate secretion while maintaining blood flow, thus strongly protecting the upper gastrointestinal tract from ulceration.
All of the following statements about stool softeners are true except
Rationale:
Stool softeners can be taken with little or no water is not true. Stool softeners require adequate fluid intake to effectively soften stool and facilitate bowel movements, preventing dehydration and ensuring proper absorption and function within the gastrointestinal tract.
A: There is minimal systemic absorption accurately reflects stool softeners' local action in the intestines, limiting systemic effects and enhancing safety for most patients.
B: The onset of action is usually 1-2 days correctly describes the typical time frame for stool softeners to exert their effect, distinguishing them from faster-acting laxatives.
C: They are useful in patients with constipation who have experienced an acute myocardial infarction highlights their safe use in vulnerable patients by avoiding straining during defecation.
Aluminum hydroxide is used to treat hyperphosphatemia associated with renal failure. Chronic use of aluminum hydroxide may cause all of the following conditions except
Rationale:
Aluminum hydroxide does not cause fluid retention.
Aluminum hydroxide binds dietary phosphate, reducing phosphate absorption and thus treating hyperphosphatemia. Chronic use can lead to phosphate depletion, causing calcium resorption and bone demineralization. Gastrointestinal side effects like anorexia and constipation are common due to aluminum's local effects on the gut, but fluid retention is not associated with its pharmacologic profile.
A: Phosphate depletion Aluminum hydroxide reduces phosphate absorption by binding it in the gut, leading to potential phosphate depletion, which is a recognized consequence of its chronic administration.
B: Calcium resorption and bone demineralization Chronic phosphate depletion triggers calcium mobilization from bones, causing resorption and demineralization, a documented adverse effect linked to aluminum hydroxide therapy.
C: Anorexia and constipation Aluminum hydroxide frequently causes gastrointestinal disturbances, including anorexia and constipation, due to its irritant effects on the digestive tract mucosa.
D: Fluid retention Fluid retention is unrelated to aluminum hydroxide’s mechanism or side effect profile; it neither influences volume status nor causes edema.
Cimetidine therapy is associated with:
Rationale:
Cimetidine therapy is associated with mental confusion in the elderly.
Cimetidine can cross the blood-brain barrier, particularly in older patients with impaired renal function, leading to central nervous system effects such as confusion, dizziness, and agitation. This neuropsychiatric side effect is more prevalent among elderly individuals due to their increased sensitivity and reduced drug clearance, making mental status changes a recognized adverse reaction during cimetidine treatment.
A: Transient increase in serum prolactin Cimetidine does not typically elevate prolactin levels; this effect is more commonly linked to drugs affecting dopamine pathways, not histamine H2 receptor antagonists like cimetidine.
B: Irreversible gynaecomastia Gynaecomastia related to cimetidine is usually reversible and linked to its antiandrogenic properties; irreversible breast enlargement lacks support in clinical observations and pharmacological profiles.
D: Asystole after rapid intravenous injection Rapid IV administration of cimetidine is not commonly associated with asystole; cardiovascular risks are minimal and generally do not include complete cardiac arrest events.
Cyclizine:
Rationale:
Cyclizine causes dry mouth. Cyclizine is an anticholinergic agent whose side effects commonly include dry mouth due to decreased salivary secretion. This adverse effect aligns with its pharmacological profile and is well-documented in clinical use, distinguishing it from other options related to receptor antagonism, teratogenicity, or specific antiemetic efficacy against morphine-induced vomiting.
A: Is a dopamine receptor antagonist Dopamine receptor antagonism is characteristic of other antiemetics like metoclopramide, but cyclizine primarily blocks histamine H1 and muscarinic receptors, not dopamine receptors, making this choice inaccurate.
B: Is effective in morphine-induced vomiting Cyclizine's antiemetic action targets vestibular and motion sickness pathways rather than opioid receptor-mediated vomiting, so its efficacy against morphine-induced nausea and vomiting is limited and not its primary indication.
C: Is a proven teratogen There is insufficient evidence categorizing cyclizine as a teratogen; it is generally considered safe during pregnancy when used appropriately, unlike known teratogenic drugs which are contraindicated due to definitive fetal risk.
Loperamide:
Rationale:
Loperamide decreases intestinal transit time. It slows down gut motility by acting on opioid receptors in the intestinal wall, thereby prolonging the time contents remain in the bowel. This effect reduces diarrhea by allowing increased absorption of fluids and electrolytes. Its primary mechanism is local to the gut, without significant systemic involvement, ensuring targeted reduction of intestinal movement.
B: Increases bulk of gut contents Loperamide does not add fiber or bulk to stool; it modulates motility rather than altering stool composition or increasing its volume within the intestines.
C: Requires systemic absorption for activity on the bowel Loperamide acts mainly locally on opioid receptors in the gut, with minimal systemic absorption, limiting central nervous system effects and focusing its action within the intestines.
D: Causes pupil constriction Loperamide does not affect the autonomic nervous system to induce miosis; its opioid receptor activity is confined to the gut, lacking effects on pupils or central nervous system.
The following is a mucosal protective agent that is effective in treatment of peptic ulcer; but produces black coloration of mouth cavity and faeces:
Rationale:
Colloidal bismuth is a mucosal protective agent effective in treating peptic ulcers and causes black coloration of the mouth cavity and feces. It forms a protective coating on ulcer sites, aiding healing. The black discoloration results from bismuth sulfide formation, a harmless but distinctive side effect that helps confirm patient compliance with the medication.
A: Omeprazole reduces gastric acid secretion but does not cause black coloration of mouth cavity or feces, nor does it primarily act as a mucosal protective agent.
B: Carbenoxolone promotes mucosal healing but lacks the side effect of black discoloration in mouth or stool, distinguishing it from colloidal bismuth.
D: Misoprostol protects gastric mucosa by prostaglandin analog action but does not induce black coloration of oral cavity or feces, differentiating it from colloidal bismuth.
Ondansetron is useful in treatment of:
Rationale:
Ondansetron is useful in treatment of vomiting induced by cancer therapy. Ondansetron is a selective 5-HT3 receptor antagonist that effectively blocks serotonin receptors involved in chemotherapy-induced nausea and vomiting. It targets the central nervous system's chemoreceptor trigger zone and gastrointestinal tract, making it especially beneficial for patients undergoing cancer treatments that trigger severe emesis, ensuring better patient comfort and treatment adherence.
B: Vomiting of pregnancy Ondansetron is not primarily indicated for pregnancy-related nausea; safer, more established antiemetics are preferred due to limited safety data and potential fetal risks, making it unsuitable as a first-line treatment in this context.
C: Motion sickness Ondansetron does not target the vestibular system or histamine receptors responsible for motion sickness. Anticholinergic or antihistamine drugs are more effective, so ondansetron lacks efficacy in preventing or treating motion sickness symptoms.
D: Acute migraine Ondansetron is not designed to treat migraine headaches or their associated vomiting. Migraine management typically involves analgesics, triptans, or antiemetics targeting different pathways, rendering ondansetron ineffective for acute migraine relief.
Which of the following antacids can be complicated with diarrhea?
Rationale:
Magnesium trisilicate can be complicated with diarrhea. Magnesium compounds, including magnesium trisilicate, have a laxative effect by increasing intestinal water content and stimulating motility, which often leads to diarrhea. This property distinguishes it from other antacids, making it important to monitor for such side effects when using magnesium-containing antacids for gastric acid neutralization or symptom relief.
A: Aluminum hydroxide Aluminum hydroxide typically causes constipation by adsorbing water in the intestines and reducing motility, contrasting with magnesium compounds that induce diarrhea; thus, it is not associated with causing diarrhea.
C: Calcium carbonate Calcium carbonate may cause constipation or belching but does not promote diarrhea; it neutralizes stomach acid without significantly affecting intestinal motility or fluid balance.
D: Sodium bicarbonate Sodium bicarbonate rapidly neutralizes acid but is more likely to cause metabolic alkalosis or gas rather than diarrhea, lacking the laxative properties seen in magnesium-based antacids.
Patient with +ve history of hepatitis c infection presents with hepatic portalsystemic encephalopathy. Which of the following drugs, given in relatively high doses, would be most suitable for the relief of signs and symptoms of this condition, and the likely underlying biochemical anomalies?
Rationale:
Lactulose is most suitable for relieving signs and symptoms of hepatic portalsystemic encephalopathy by reducing blood ammonia levels through its cathartic effect and altering gut flora to decrease ammonia production. This mechanism targets the biochemical abnormalities caused by liver dysfunction and portal-systemic shunting in hepatitis C patients, improving neurological symptoms effectively.
A: Diphenoxylate slows gastrointestinal motility but does not address ammonia reduction or hepatic encephalopathy’s underlying biochemical disturbances, making it unsuitable for this condition.
B: Lansoprazole reduces gastric acid secretion without influencing ammonia metabolism or neurotoxic effects, thus lacking therapeutic benefit in hepatic portalsystemic encephalopathy.
D: Loperamide controls diarrhea by reducing intestinal motility but fails to lower ammonia levels or modify gut flora, rendering it ineffective for hepatic encephalopathy treatment.
A patient who is taking verapamil for hypertension and angina has become constipated. Which of the following drugs is an osmotic laxative that could be used to treat the patient's constipation?
Rationale:
Magnesium hydroxide is an osmotic laxative that can be used to treat constipation by drawing water into the intestines, softening stools, and promoting bowel movements. Its mechanism involves osmotic retention of fluid, which effectively counteracts the constipating effects of verapamil, a calcium channel blocker known to slow gastrointestinal motility.
A: Aluminum hydroxide acts primarily as an antacid, neutralizing stomach acid rather than affecting bowel movements, so it lacks the osmotic properties required to relieve constipation caused by verapamil.
B: Diphenoxylate is an antidiarrheal agent that slows intestinal motility, which would worsen constipation rather than alleviate it in this patient.
D: Metoclopramide is a prokinetic that enhances gastrointestinal motility but does not have osmotic laxative effects and is not suitable for treating constipation.
In case of hill journey, antimotion sickness drugs are best administered at
Rationale:
Antimotion sickness drugs are best administered one hour before commencing the journey.
Administering antimotion sickness drugs one hour prior allows sufficient time for the medication to absorb and reach effective plasma concentrations, thereby preventing the onset of symptoms during the hill journey. This preemptive approach ensures optimal drug efficacy, reducing nausea and discomfort associated with motion sickness before exposure to the causative motion.
A: Twelve hours before commencing journey Administering drugs too early may lead to reduced efficacy during the journey since the medication’s active concentration could diminish before exposure to motion stimuli.
C: Immediately after commencing journey Starting medication post-journey onset may delay relief, permitting nausea and dizziness to develop, reducing overall effectiveness in preventing motion sickness symptoms.
D: At the first feeling of motion sickness Delaying drug intake until symptoms appear allows discomfort to start, limiting the preventive potential of the medication and increasing the risk of severe motion sickness.
Cancer chemotherapy induced vomiting that is not controlled by metoclopramide alone can be suppressed by combining it with
Rationale:
Combining metoclopramide with dexamethasone effectively suppresses chemotherapy-induced vomiting not controlled by metoclopramide alone. Dexamethasone enhances antiemetic effects through anti-inflammatory and antiemetic properties, improving control of nausea and vomiting. Its synergistic action with metoclopramide targets multiple emetic pathways, making it a superior adjunct therapy in managing refractory chemotherapy-induced emesis.
A: Amphetamine lacks antiemetic properties and primarily acts as a stimulant; it does not influence the emetic pathways involved in chemotherapy-induced vomiting, making it ineffective as an adjunct to metoclopramide.
C: Hyoscine primarily treats motion sickness and has anticholinergic effects; it does not adequately target the mechanisms of chemotherapy-induced vomiting, limiting its usefulness in this context.
D: Cyclizine is an antihistamine used for motion sickness but is less effective than dexamethasone in chemotherapy-induced vomiting and lacks the synergistic benefits with metoclopramide.